Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INKT NYSE:JATT NASDAQ:NRSN NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINKTMiNK Therapeutics$14.00-3.8%$14.56$4.56▼$76.00$63.28M0.33341,165 shs36,372 shsJATTJATT Acquisition$4.51+3.9%$2.23$7.80▼$12.38$77.80MN/A41,322 shs1.08 million shsNRSNNeuroSense Therapeutics$1.19-4.8%$1.19$0.80▼$2.60$16.67M1.61357,642 shs223,521 shsNRXPNRx Pharmaceuticals$3.17-11.0%$2.83$1.10▼$6.01$62.80M1.74498,435 shs654,589 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINKTMiNK Therapeutics-0.27%-5.89%-5.27%-77.33%+114.92%JATTJATT Acquisition+4.08%+7.43%+96.38%+212.23%+9.05%NRSNNeuroSense Therapeutics+2.46%+1.63%+6.84%-39.61%+2.17%NRXPNRx Pharmaceuticals-0.56%+6.91%+13.02%+10.90%+142.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINKTMiNK Therapeutics$14.00-3.8%$14.56$4.56▼$76.00$63.28M0.33341,165 shs36,372 shsJATTJATT Acquisition$4.51+3.9%$2.23$7.80▼$12.38$77.80MN/A41,322 shs1.08 million shsNRSNNeuroSense Therapeutics$1.19-4.8%$1.19$0.80▼$2.60$16.67M1.61357,642 shs223,521 shsNRXPNRx Pharmaceuticals$3.17-11.0%$2.83$1.10▼$6.01$62.80M1.74498,435 shs654,589 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINKTMiNK Therapeutics-0.27%-5.89%-5.27%-77.33%+114.92%JATTJATT Acquisition+4.08%+7.43%+96.38%+212.23%+9.05%NRSNNeuroSense Therapeutics+2.46%+1.63%+6.84%-39.61%+2.17%NRXPNRx Pharmaceuticals-0.56%+6.91%+13.02%+10.90%+142.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINKTMiNK Therapeutics 2.33Hold$37.50161.87% UpsideJATTJATT Acquisition 0.00N/AN/AN/ANRSNNeuroSense Therapeutics 2.50Moderate Buy$14.001,048.48% UpsideNRXPNRx Pharmaceuticals 2.71Moderate Buy$34.50961.54% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, INKT, JATT, and NRXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025INKTMiNK TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NRSNNeuroSense TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NRXPNRx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025INKTMiNK TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NRSNNeuroSense TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NRXPNRx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/10/2025NRXPNRx PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/8/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/8/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/AJATTJATT AcquisitionN/AN/A$0.17 per share27.08($0.53) per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ANRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)Latest NRSN, INKT, JATT, and NRXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31-$0.98-$0.67-$0.98N/AN/A8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINKTMiNK TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINKTMiNK TherapeuticsN/A0.150.15JATTJATT AcquisitionN/A0.150.15NRSNNeuroSense TherapeuticsN/A0.71N/ANRXPNRx PharmaceuticalsN/A0.110.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINKTMiNK Therapeutics2.87%JATTJATT Acquisition47.97%NRSNNeuroSense Therapeutics1.04%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipINKTMiNK Therapeutics22.48%JATTJATT Acquisition20.00%NRSNNeuroSense Therapeutics27.40%NRXPNRx Pharmaceuticals19.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataJATTJATT Acquisition317.25 million13.80 millionNot OptionableNRSNNeuroSense Therapeutics10N/AN/ANot OptionableNRXPNRx Pharmaceuticals219.81 million16.05 millionOptionableNRSN, INKT, JATT, and NRXP HeadlinesRecent News About These CompaniesWeiss Ratings Reaffirms "Sell (D-)" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)October 10 at 8:33 AM | marketbeat.comNRx Pharmaceuticals (NRXP) Strengthens Pipeline With Dual Pathways for Ketamine-Based TherapiesOctober 10 at 5:33 AM | finance.yahoo.comNRx Pharmaceuticals (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based TherapiesOctober 10 at 5:33 AM | msn.comNRx Pharmaceuticals (NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity ConferenceOctober 7 at 12:07 AM | finance.yahoo.comNRx Pharmaceuticals (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity ConferenceOctober 6, 2025 | financial-news.co.ukNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity ConferenceOctober 6, 2025 | markets.businessinsider.comNRx Pharmaceuticals and HOPE Therapeutics to Present at Noble Capital Markets Emerging Growth Virtual Equity ConferenceOctober 6, 2025 | quiverquant.comQNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity ConferenceOctober 6, 2025 | globenewswire.comNRx Pharmaceuticals (NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)October 1, 2025 | finance.yahoo.comNRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at HC WainwrightOctober 1, 2025 | marketbeat.comNRx Pharmaceuticals (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)September 30, 2025 | financial-news.co.ukNRx Pharmaceuticals Refiles ANDA for KETAFREE™, a Preservative-Free IV Ketamine Formulation Amid Drug ShortageSeptember 29, 2025 | quiverquant.comQNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV KetamineSeptember 29, 2025 | globenewswire.comNRX Pharmaceuticals Gains FDA Approval for KETAFREE™September 26, 2025 | msn.comD. Boral Capital Maintains NRx Pharmaceuticals (NRXP) Buy RecommendationSeptember 25, 2025 | msn.comNRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral CapitalSeptember 25, 2025 | marketbeat.comNRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine ProductSeptember 25, 2025 | financial-news.co.ukNRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine ProductSeptember 25, 2025 | finance.yahoo.comNew to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx ...September 24, 2025 | leadertelegram.comLNRX Pharmaceuticals stock surges after FDA grants Suitability PetitionSeptember 24, 2025 | za.investing.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative ...September 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, INKT, JATT, and NRXP Company DescriptionsMiNK Therapeutics NASDAQ:INKT$14.00 -0.55 (-3.78%) Closing price 04:00 PM EasternExtended Trading$14.37 +0.37 (+2.61%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.JATT Acquisition NYSE:JATT$4.51 +0.17 (+3.92%) As of 10/9/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.NeuroSense Therapeutics NASDAQ:NRSN$1.19 -0.06 (-4.80%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.NRx Pharmaceuticals NASDAQ:NRXP$3.17 -0.39 (-10.96%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.08 (+2.37%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
